[go: up one dir, main page]

CY1112957T1 - Μη νευροτοξικοι παραγοντες, οι οποιοι ενεργοποιουν το πλασμινογονο για τη θεραπευτικη αγωγη εγκεφαλικου επεισοδιου - Google Patents

Μη νευροτοξικοι παραγοντες, οι οποιοι ενεργοποιουν το πλασμινογονο για τη θεραπευτικη αγωγη εγκεφαλικου επεισοδιου

Info

Publication number
CY1112957T1
CY1112957T1 CY20121100407T CY121100407T CY1112957T1 CY 1112957 T1 CY1112957 T1 CY 1112957T1 CY 20121100407 T CY20121100407 T CY 20121100407T CY 121100407 T CY121100407 T CY 121100407T CY 1112957 T1 CY1112957 T1 CY 1112957T1
Authority
CY
Cyprus
Prior art keywords
neurototoxic
plasminogene
factors
treatment
treatment introduction
Prior art date
Application number
CY20121100407T
Other languages
English (en)
Inventor
Mariola Sohngen
Wolfgang Sohngen
Wolf-Dieter Schleuning
Robert Medcalf
Original Assignee
H. Lundbeck A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H. Lundbeck A/S filed Critical H. Lundbeck A/S
Publication of CY1112957T1 publication Critical patent/CY1112957T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6459—Plasminogen activators t-plasminogen activator (3.4.21.68), i.e. tPA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21068—Tissue plasminogen activator (3.4.21.68), i.e. tPA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)

Abstract

Η εφεύρεση αφορά τη χρήση και παραγωγή μη νευροτοξικών παραγόντων ενεργοποίησης πλασμινογόνου, παραδείγματος χάριν από Desmodus rotundus (DSΡΑ) για τη θεραπευτική αγωγή του εγκεφαλικού επεισοδίου εις τον άνθρωπο για την προσφορά μιας νέας θεραπευτικής προσέγγισης για τη θεραπευτική αγωγή του εγκεφαλικού επεισοδίου εις τον άνθρωπο.
CY20121100407T 2001-11-02 2012-04-30 Μη νευροτοξικοι παραγοντες, οι οποιοι ενεργοποιουν το πλασμινογονο για τη θεραπευτικη αγωγη εγκεφαλικου επεισοδιου CY1112957T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10153601A DE10153601A1 (de) 2001-11-02 2001-11-02 DSPA zur Behandlung von Schlaganfall
EP01130006A EP1308166B1 (de) 2001-11-02 2001-12-17 Nicht-neurotoxische Plasminogen Aktivierende Faktoren zur Behandlung von Schlaganfällen
EP08012976A EP1997510B1 (de) 2001-11-02 2002-10-31 Nicht-neurotoxische Plasminogen Aktivierende Faktoren zur Behandlung von Schlaganfall

Publications (1)

Publication Number Publication Date
CY1112957T1 true CY1112957T1 (el) 2016-04-13

Family

ID=7704253

Family Applications (3)

Application Number Title Priority Date Filing Date
CY20081101193T CY1108446T1 (el) 2001-11-02 2008-10-23 Μη νευροτοξικοι παραγοντες ενεργοποιησης πλασμινογονου για την αντιμετωπιση αποπληξιας
CY20091101206T CY1109648T1 (el) 2001-11-02 2009-11-19 Μη νευροτοξικοι παραγοντες ενεργοποιησης πλασμινογονου για την αγωγη εγκεφαλικου επεισοδιου
CY20121100407T CY1112957T1 (el) 2001-11-02 2012-04-30 Μη νευροτοξικοι παραγοντες, οι οποιοι ενεργοποιουν το πλασμινογονο για τη θεραπευτικη αγωγη εγκεφαλικου επεισοδιου

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CY20081101193T CY1108446T1 (el) 2001-11-02 2008-10-23 Μη νευροτοξικοι παραγοντες ενεργοποιησης πλασμινογονου για την αντιμετωπιση αποπληξιας
CY20091101206T CY1109648T1 (el) 2001-11-02 2009-11-19 Μη νευροτοξικοι παραγοντες ενεργοποιησης πλασμινογονου για την αγωγη εγκεφαλικου επεισοδιου

Country Status (27)

Country Link
US (7) US20050048027A1 (el)
EP (4) EP1308166B1 (el)
JP (2) JP5004407B2 (el)
KR (3) KR100816221B1 (el)
CN (2) CN101156948A (el)
AT (3) ATE440614T1 (el)
AU (1) AU2002350660C1 (el)
BR (1) BR0213856A (el)
CA (1) CA2465792C (el)
CY (3) CY1108446T1 (el)
DE (3) DE10153601A1 (el)
DK (3) DK1308166T3 (el)
EA (3) EA013707B1 (el)
ES (3) ES2332576T3 (el)
HK (1) HK1057328A1 (el)
HR (1) HRP20040383B1 (el)
HU (1) HU230163B1 (el)
IL (1) IL205695A0 (el)
MX (1) MXPA04004155A (el)
NO (1) NO329789B1 (el)
NZ (2) NZ545414A (el)
PL (1) PL208343B1 (el)
PT (3) PT1308166E (el)
SG (1) SG148034A1 (el)
SI (2) SI1441757T1 (el)
WO (1) WO2003037363A2 (el)
ZA (1) ZA200403285B (el)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10153601A1 (de) 2001-11-02 2003-05-22 Paion Gmbh DSPA zur Behandlung von Schlaganfall
AU2003227721A1 (en) * 2003-05-02 2004-11-23 Paion Gmbh Intravenous injection of non-neurotoxic plasminogen activators for the treatment of stroke
US20060135425A1 (en) * 2003-05-02 2006-06-22 Paion Deutschland Gmbh Intravenous injection of plasminogen non-neurotoxic activators for treating cerebral stroke
US20080057050A1 (en) * 2003-05-02 2008-03-06 Paion Deutschland Gmbh Intravenous injection of plasminogen non-neurotoxic activators for treating cerebral stroke
CA2524573A1 (en) * 2003-05-02 2004-11-11 Paion Deutschland Gmbh Intravenous injection of non-neurotoxic plasminogen activators for the treatment of stroke
BRPI0410055A (pt) * 2003-05-05 2006-04-25 Paion Deutschland Gmbh antagonistas de receptor de glutamato como neuroprotetores
DE10342518A1 (de) * 2003-09-12 2005-05-12 Paion Gmbh Plasminogen-Aktivatoren mit verringerter Lysin-Bindungskapazität
JP2006241109A (ja) * 2005-03-04 2006-09-14 Paion Deutschland Gmbh ヒトＰセレクチンおよびＤＳＰＡα１に対する抗体を含む融合タンパク質
TWI482628B (zh) * 2007-10-18 2015-05-01 Lundbeck & Co As H 新穎之血栓溶解病患次群
EP2558580A2 (en) 2010-04-16 2013-02-20 H. Lundbeck A/S Method for the manufacture of recombinant dspa alpha1
MX337248B (es) * 2011-01-05 2016-02-19 Thrombogenics Nv Variantes de plasminogeno y plasmina.
CA2844644A1 (en) 2011-08-12 2013-02-21 Thrombogenics N.V. Plasminogen and plasmin variants
US11613744B2 (en) 2018-12-28 2023-03-28 Vertex Pharmaceuticals Incorporated Modified urokinase-type plasminogen activator polypeptides and methods of use
PH12021551405A1 (en) 2018-12-28 2022-05-11 Vertex Pharma Modified urokinase-type plasminogen activator polypeptides and methods of use

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR79202B (el) 1982-05-05 1984-10-22 Genentech Inc
US4766075A (en) * 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
US5244806A (en) * 1985-08-26 1993-09-14 Eli Lilly And Company DNA encoding novel tissue plasminogen activator derivatives having kringles 1 and 2 deleted, vectors and host cells
DE3643158A1 (de) 1986-04-21 1987-11-19 Boehringer Mannheim Gmbh Gewebs-plasminogen-aktivator(tpa) - derivat und seine herstellung
JPH087179B2 (ja) * 1986-09-27 1996-01-29 日本碍子株式会社 ガスセンサ
WO1988005081A2 (en) * 1986-12-30 1988-07-14 Cetus Corporation Novel plasminogen activator
IL87276A (en) * 1987-08-03 1995-07-31 Fujisawa Pharmaceutical Co Analog of tissue plasminogen activator comprising only the kringle 2 and protease domain dna encoding the same processes for the preparation thereof and pharmaceutical compositions containing the same
EP0386240B1 (en) * 1987-10-29 1995-07-19 Yamanouchi Pharmaceutical Co. Ltd. Novel polypeptide compounds
US5094953A (en) 1988-03-21 1992-03-10 Genentech, Inc. Human tissue plasminogen activator variants
DK176140B1 (da) 1988-07-20 2006-09-25 Schering Ag Patentabteilung Flagermusspyt-plasminogenaktivatorer
DE3825253A1 (de) 1988-07-25 1990-02-01 Boehringer Mannheim Gmbh T-pa-derivat und seine herstellung
US5714145A (en) * 1988-09-02 1998-02-03 Genentech, Inc. Tissue plasminogen activator having zymogenic or fibrin specific properties
JPH0273774A (ja) * 1988-09-09 1990-03-13 Nec Corp ファクシミリ装置
GB8901422D0 (en) * 1989-01-23 1989-03-15 Fujisawa Pharmaceutical Co New tissue plasminogen activator
DE3903581A1 (de) * 1989-02-07 1990-08-16 Boehringer Mannheim Gmbh Gewebs-plasminogenaktivator-derivat
US5676947A (en) * 1989-02-07 1997-10-14 Boehringer Manneheim Gmbh Method for treating thromboembolic conditions using thrombolytically active proteins
DE3917949A1 (de) * 1989-05-30 1991-01-24 Schering Ag Neues thrombolytikum
DE3904580A1 (de) 1989-02-13 1990-08-16 Schering Ag Neues thrombolytikum
US6008019A (en) * 1989-02-13 1999-12-28 Schering Aktiengesellschaft Plasminogen activator from saliva of the vampire bat
DE69024382T2 (de) * 1989-02-13 1996-08-14 Schering Ag, 13353 Berlin Fledermausspeichel-Plasminogenaktivator vPA-alpha 1
ATE197067T1 (de) * 1989-04-07 2000-11-15 Cancerforskningsfonden Af 1989 Plasminogen-aktivator-rezeptor vom urokinasetyp
US5891664A (en) * 1989-04-07 1999-04-06 Cancerforskningsfondet Af 1989 Vectors and methods for recombinant production of uPA-binding fragments of the human urokinase-type plasminogen receptor (uPAR)
JPH0352119A (ja) * 1989-07-19 1991-03-06 Matsushita Electric Ind Co Ltd 光学式記録再生装置
NL8902454A (nl) 1989-10-03 1991-05-01 Stichting Centraal Lab Mutanten van de humane plasminogeen activator inhibitor 1 (pai-1), hun bereiding en toepassing, en recombinante polynucleotiden die voor deze mutanten coderende genetische informatie omvatten.
US5326700A (en) * 1990-11-06 1994-07-05 Eli Lilly And Company DNA sequences encoding t-PA derivatives with cleavable sites
ES2082465T3 (es) * 1991-04-16 1996-03-16 Boehringer Mannheim Gmbh Unidad farmaceutica de envasado que contiene activadores de plasminogeno para la administracion multiple de bolos.
DE4123845A1 (de) * 1991-07-18 1993-01-21 Boehringer Mannheim Gmbh Pharmazeutische verpackungseinheit enthaltend plasminogenaktivatoren zur mehrfachbolusgabe
US5595736A (en) * 1991-04-22 1997-01-21 Eli Lilly And Company Compounds and methods for treatment of thromboembolic disorders
NL9101520A (nl) * 1991-09-09 1993-04-01 Stork Fibron Bv Werkwijze voor het vervaardigen van een eetbaar produkt.
ATE145669T1 (de) 1991-12-16 1996-12-15 Genentech Inc T-pa substitutionsvarianten mit verbesserter fibrinspezifität
RU2183214C2 (ru) * 1992-12-04 2002-06-10 Шеринг Аг Природный и рекомбинантный ингибиторы тромбина, их получение и применение
US5510330A (en) * 1994-03-25 1996-04-23 Boehringer Mannheim Gmbh Combinations of thrombolytically active proteins and non-heparin anticoagulants, and uses thereof.
GB9412131D0 (en) * 1994-06-17 1994-08-10 British Bio Technology Thrombolytic composition
DE4423574A1 (de) 1994-07-05 1996-01-11 Boehringer Mannheim Gmbh Nicht-glykosylierte Plasminogenaktivator-Derivate und ihre Verwendung bei erhöhtem Blutungsrisiko
US5827832A (en) 1995-03-06 1998-10-27 Interneuron Pharmaceuticals, Inc. Method of protecting brain tissue from cerebral infarction subsequent to ischemia
US5786187A (en) * 1995-09-21 1998-07-28 The Research Foundation Of State University Of New York Method for reducing neuronal degeneration associated with seizure
US5945432A (en) * 1995-12-22 1999-08-31 The University Of Vermont And State Agricultural College Thrombolytic agents and thienopyridine derivatives in acute stroke
US20020081294A1 (en) * 1996-01-23 2002-06-27 Genentech, Inc. Co-administration of a thrombolytic and an anti-CD18 antibody in stroke
US5731186A (en) * 1996-02-05 1998-03-24 Schering Aktiengesellschaft Method for the production of rDSPA α1
US6235947B1 (en) * 1997-04-14 2001-05-22 Takeda Chemical Industries, Ltd. D-mannitol and its preparation
US5830349A (en) * 1996-07-22 1998-11-03 Dana Corporation Flow inverter for filters
BR9711840A (pt) * 1996-10-01 1999-08-24 Univ Georgia Res Found Agentes de controle de insetos biolÄgico expressando os genes para toxinas de caro especificas para insetos m-todos e composi-{es
US6008109A (en) * 1997-12-19 1999-12-28 Advanced Micro Devices, Inc. Trench isolation structure having a low K dielectric encapsulated by oxide
KR20010069066A (ko) 2000-01-12 2001-07-23 이종원 저산소 농도하에서 생존이 가능하도록 하는 동물세포의배양방법
DE10008646A1 (de) 2000-02-24 2001-09-13 Kempten Elektroschmelz Gmbh Beschichteter Formkörper aus Siliciumnitrid
GB0025473D0 (en) * 2000-10-17 2000-11-29 Pfizer Ltd Pharmaceutical combinations
US20020089179A1 (en) * 2000-12-30 2002-07-11 Levon Guyumjan Hose coupling apparatus and method
DE10153601A1 (de) 2001-11-02 2003-05-22 Paion Gmbh DSPA zur Behandlung von Schlaganfall
US20080057050A1 (en) * 2003-05-02 2008-03-06 Paion Deutschland Gmbh Intravenous injection of plasminogen non-neurotoxic activators for treating cerebral stroke
US20060135425A1 (en) * 2003-05-02 2006-06-22 Paion Deutschland Gmbh Intravenous injection of plasminogen non-neurotoxic activators for treating cerebral stroke
AU2003227721A1 (en) 2003-05-02 2004-11-23 Paion Gmbh Intravenous injection of non-neurotoxic plasminogen activators for the treatment of stroke
CA2524573A1 (en) 2003-05-02 2004-11-11 Paion Deutschland Gmbh Intravenous injection of non-neurotoxic plasminogen activators for the treatment of stroke
BRPI0410055A (pt) * 2003-05-05 2006-04-25 Paion Deutschland Gmbh antagonistas de receptor de glutamato como neuroprotetores
US20050085478A1 (en) 2003-08-22 2005-04-21 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a low-molecular-weight heparin for the treatment of central nervous system damage
DE10342518A1 (de) 2003-09-12 2005-05-12 Paion Gmbh Plasminogen-Aktivatoren mit verringerter Lysin-Bindungskapazität
TWI482628B (zh) * 2007-10-18 2015-05-01 Lundbeck & Co As H 新穎之血栓溶解病患次群

Also Published As

Publication number Publication date
EP1308166A1 (de) 2003-05-07
US20090263373A1 (en) 2009-10-22
EP1441757B1 (de) 2008-07-23
ATE440614T1 (de) 2009-09-15
US20090004176A1 (en) 2009-01-01
PT1441757E (pt) 2008-11-03
PT1997510E (pt) 2012-05-21
EA200801714A1 (ru) 2008-12-30
CN1592634A (zh) 2005-03-09
EA010858B1 (ru) 2008-12-30
AU2002350660C1 (en) 2008-10-09
EP1997510A8 (de) 2011-04-13
EP1308166B1 (de) 2009-08-26
SG148034A1 (en) 2008-12-31
US8071091B2 (en) 2011-12-06
IL205695A0 (en) 2010-11-30
ZA200403285B (en) 2005-07-27
MXPA04004155A (es) 2005-03-31
EA200400624A1 (ru) 2004-10-28
CN100446810C (zh) 2008-12-31
CA2465792C (en) 2014-04-01
NZ545414A (en) 2008-09-26
DE50212548D1 (de) 2008-09-04
HRP20040383A2 (en) 2005-08-31
JP2005519025A (ja) 2005-06-30
US20060142195A1 (en) 2006-06-29
DK1441757T3 (da) 2008-11-17
EP2368567A1 (de) 2011-09-28
CA2465792A1 (en) 2003-05-08
KR20070087248A (ko) 2007-08-27
EP1997510A1 (de) 2008-12-03
CN101156948A (zh) 2008-04-09
AU2002350660B2 (en) 2008-04-10
JP2009137983A (ja) 2009-06-25
ATE547115T1 (de) 2012-03-15
ATE401910T1 (de) 2008-08-15
EA013707B1 (ru) 2010-06-30
DK1997510T3 (da) 2012-05-21
PL208343B1 (pl) 2011-04-29
ES2332576T3 (es) 2010-02-09
NO329789B1 (no) 2010-12-20
EP1441757A2 (de) 2004-08-04
US20050048027A1 (en) 2005-03-03
HK1057328A1 (en) 2004-04-02
HUP0402165A2 (hu) 2005-01-28
US20130039902A1 (en) 2013-02-14
DE10153601A1 (de) 2003-05-22
DK1308166T3 (da) 2009-12-14
JP5004407B2 (ja) 2012-08-22
ES2311070T3 (es) 2009-02-01
PT1308166E (pt) 2009-11-27
SI1441757T1 (sl) 2009-02-28
KR100816221B1 (ko) 2008-03-24
US20170051268A1 (en) 2017-02-23
NO20042262D0 (no) 2004-06-01
US20140199287A1 (en) 2014-07-17
HU230163B1 (hu) 2015-09-28
ES2382224T3 (es) 2012-06-06
SI1997510T1 (sl) 2012-06-29
HRP20040383B1 (en) 2012-08-31
CY1108446T1 (el) 2014-04-09
WO2003037363A2 (de) 2003-05-08
PL369872A1 (en) 2005-05-02
CY1109648T1 (el) 2014-08-13
DE50115077D1 (de) 2009-10-08
KR20050042234A (ko) 2005-05-06
NO20042262L (no) 2004-06-01
WO2003037363A3 (de) 2003-09-18
KR20090128583A (ko) 2009-12-15
HUP0402165A3 (en) 2010-01-28
BR0213856A (pt) 2004-08-31
EA201000386A1 (ru) 2011-06-30
US8119597B2 (en) 2012-02-21
EP1997510B1 (de) 2012-02-29
NZ532903A (en) 2006-10-27

Similar Documents

Publication Publication Date Title
CY1112957T1 (el) Μη νευροτοξικοι παραγοντες, οι οποιοι ενεργοποιουν το πλασμινογονο για τη θεραπευτικη αγωγη εγκεφαλικου επεισοδιου
CY1106032T1 (el) Υποκατασταθεισες πυραζολες
DK1525177T3 (da) Substituerede 1,3-diphenylprop-2-en-1-on-derivater, fremstilling og anvendelse deraf
CY1111237T1 (el) Χρηση πραμιπεξολης για αντιμετωπιση αμυοτροφικης πλευρικης σκληρυνσης
YU9404A (sh) Multimerna, usmerena kontrastna sredstva na bazi peptida
CY1110547T1 (el) Συμπυκνωμενα πρωτεϊνικα σκευασματα μειωμενου ιξωδους
SE0100901D0 (sv) New composition
CY1109275T1 (el) ΠΑΡΑΓΩΓΑ α-(Ν-ΣΟΥΛΦΟΝΑΜΙΔΟ)ΑΚΕΤΑΜΙΔΙΟΥ ΩΣ ΑΝΑΣΤΟΛΕΙΣ β-ΑΜΥΛΟΕΙΔΟΥΣ
WO2003005999A8 (en) Methods of treating cytokine mediated diseases
CY1108610T1 (el) Πεπτιδια της il-2 και παραγωγα αυτων και χρηση αυτων ως θεραπευτικοι παραγοντες
IS6491A (is) Pteridínefnasambönd til meðhöndlunar á sóríasis
ATE299493T1 (de) N-cyanomethylamide als protease inhibitoren
DK1349856T3 (da) Isoindolin-1-on-glucokinase-aktivatorer
NO20033220D0 (no) Inhibitorer for cruzipain og andre cysteinproteaser
WO2003104425A3 (en) NEW STABLE ANTI-CD22 ANTIBODIES
SE0101932D0 (sv) Pharmaceutical combinations
HRP20050903B1 (hr) Intravenska injekcija ne-neurotoksiäśnih aktivatora plazminogena za tretman kapi
NO20073914L (no) Biologisk aktive peptider
DE60224667D1 (de) Perylenequinonen zur anwendung als sonosensitizer
PL372769A1 (en) Cyanoguanidine prodrugs
CY1114254T1 (el) Ενδοφλεβια ενεση μη νευροτοξικων ενεργοποιητων του πλασμινογονου για την αντιμετωπιση του εγκεφαλικου επεισοδιου
DE50204475D1 (de) Präparationen von vitamin e in kombination mit afamin
ATE328082T1 (de) Verkürztes bard1 protein und dessen diagnostische und therapeutische anwendungen
EP1566386A4 (en) GENUS IN CONNECTION WITH HAIR LOSS, THE POLYPEPTIDE ENCODED THEREON AND APPLICATIONS THEREOF
DE50310541D1 (de) Proteolyseresistenter aktiver vegf